Long-term Follow-up of Long-acting Cabotegravir (CAB LA) for PrEP (Pre-exposure Prophylaxis) in Participants at Risk of Acquiring HIV (Human Immunodeficiency Virus) - Trial NCT06134362
Access comprehensive clinical trial information for NCT06134362 through Pure Global AI's free database. This Phase 3 trial is sponsored by ViiV Healthcare and is currently Not yet recruiting. The study focuses on HIV Infections. Target enrollment is 3500 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
ViiV Healthcare
Timeline & Enrollment
Phase 3
Jan 05, 2024
Mar 31, 2027
Primary Outcome
Number of participants with new HIV infection,Number of participants with new HIV infection by characteristic
Summary
The purpose of this study is long-term evaluation of long-acting injectable cabotegravir (CAB
 LA) for HIV pre-exposure prophylaxis (PrEP) in eligible participants who have completed DAIDS
 (Division of AIDS) sponsored studies HPTN 083 and HPTN 084 and associated sub-studies.
 Participants will continue receiving CAB LA and be followed for new HIV diagnosis, SAEs
 (serious adverse events), Grade 3 and Grade 4 ISRs (injection site reactions), and AEs
 (adverse events) leading to withdrawal.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06134362
Non-Device Trial